Section Arrow
Quote
CYCC.NASDAQ
- Cyclacel Pharmaceuticals Inc
Quotes are at least 15-min delayed:2025/09/02 19:38 EDT
After Hours
Last
 7.8
+0.11 (+1.43%)
Bid
7.7
Ask
7.81
High 7.98 
Low 7.68 
Volume 2795 
Regular Hours
Last
 7.69
-0.545 (-6.62%)
Day High 
8.11 
Prev. Close
8.235 
1-M High
10.58 
Volume 
41.14K 
Bid
7.7
Ask
7.81
Day Low
7.6006 
Open
8.11 
1-M Low
6.91 
Market Cap 
18.44M 
Currency USD 
P/E 0 
%Yield -- 
10-SMA 7.75 
20-SMA 8.24 
50-SMA 8.16 
52-W High 597.6 
52-W Low 3.0801 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
7,123.50/-1.12
Enterprise Value
18.44M
Balance Sheet
Book Value Per Share
1.62
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
0.17
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CARMCarisma Therapeutics0.44+0.225+104.65%-- 
After Hours 0.375 -0.065 -14.77%
MNKDMannKind Corp5.74+1.15+25.05%41.45PE
After Hours 5.79 +0.05 +0.87%
CRMDCorMedix14.64-0.19-1.28%19.01PE
After Hours 14.77 +0.13 +0.89%
ADAPAdaptimmune Therapeutics plc0.0578-0.0011-1.87%-- 
After Hours 0.0581 +0.0003 +0.52%
HOTHHoth Therapeutics1.28+0.12+10.34%-- 
After Hours 1.21 -0.07 -5.47%
Quotes are at least 15-min delayed：2025/09/02 19:38 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.